Flat sales growth for Schering's contrast media
This article was originally published in Clinica
Executive Summary
German company Schering's contrast media sales rose only 1% to DM 1,203 million ($800 million) in the first nine months of 1996. Contrast media sales in the US, however, rose 60%. This is due to considerable volume growth of Ultravist and Magnevist, which is largely attributable to Schering's distribution agreement with Abbott (see Clinica No 711, p 11). The continued decline in sales of Iopamiron in Japan is due to exchange rate effects.